Diabetes

States that expanded Medicaid coverage under the Affordable Care Act have seen a 23% increase in the number of newly diagnosed diabetes patients.

The FDA has approved a new treatment for 1 of the most common diabetic eye diseases.

Glyxambi is now available by prescription at pharmacies across the United States.

Lower co-pays contribute to higher medication adherence.

A pharmacy school team nabbed second place in the Mississippi Public Universities' Blueprint Mississippi Social Business Challenge.

Pharmacists and other health care providers often do not advise patients with mental illness symptoms and diabetes to make lifestyle changes that would reduce related health risks.

Women who smoke during pregnancy may be putting their children at risk for developing diabetes in adulthood.

As the US Centers for Medicare and Medicaid Services places a greater emphasis on medication adherence through its star ratings, pharmacists and other health care professionals continue to seek ways to improve adherence among seniors.

From optimizing inhaler technique in patients with chronic obstructive pulmonary disease, to catching red flags when dispensing controlled substances to patients with chronic pain, pharmacists can improve patient outcomes in an evolving treatment landscape.

Taking multiple medications, having hypertension, and executing heavy labor at work are all associated with a lower sperm count among men attempting to conceive.

Type 2 diabetes may be associated with impairments in cognitive abilities, such as working memory and verbal fluency.

Improvements in nutrition, exercise, stress, and sleep may help patients with prediabetes reduce their risk of progressing to type 2 diabetes.

Including often-ignored random blood glucose values in screening guidelines could help clinicians detect diabetes risk.

In light of misrepresented statistics and overstated fears about statin-related adverse events, here are 3 of the biggest myths your patients may have heard about these life-saving medications-and the facts

Beyond working in traditional retail, community, and health-system settings, pharmacy students have a lot of options. Two Roosevelt University pharmacy students are proof of that.

Sanofi has announced the FDA approval of its insulin glargine injection (Toujeo), a once-daily long-acting basal insulin, for the improvement of glycemic control in adults with type 1 and type 2 diabetes.

Novo Nordisk has positive results from a completed phase 2 trial on the oral formulation of its investigational, long-acting human glucagon-like peptide-1 analogue.

Many patients with non-alcoholic fatty liver disease also have low vitamin D levels.

Diabetics who took metformin saw a decreased chance of developing adenocarcinoma.

Several studies have reported that controlling blood pressure with medication improves cardiovascular outcomes.

College freshmen face tremendous pressure, often trying to adjust to tough academic standards while living away from home for the first time. The stress of freshman year can be multiplied when the student is managing a chronic disease such as type 1 diabetes.

Karolinska Institutet and Novo Nordisk today signed a collaboration agreement in the field of diabetes. The programme will be fully funded by Novo Nordisk.

Although the American Diabetes Association recommends that adult patients with diagnosed diabetes visit a health care professional biannually to achieve and maintain glycemic control, a recent report from the National Center for Health Statistics in the US Centers for Disease Control and Prevention shows that 1 in 5 younger diabetics have not done so in the past 6 months.

The FDA today expanded the indication of Roche's ranibizumab (Lucentis), approving the drug for the treatment of diabetic retinopathy in patients with diabetic macular edema.

The American Pharmacists Association is pleased to announce that the association's education team and The Pharmacist & Patient-Centered Diabetes Care Certificate Training Program were honored with the 2015 Award for Outstanding Live CE Activity by the Alliance for Continuing Education in the Health Professions.

Sanofi and MannKind Corp. have announced the US launch of their Afrezza Inhalation Powder, the first and only insulin approved for administration via inhalation.

Limiting added sugars could be among the most effective strategies for reducing the prevalence of type 2 diabetes.

The FDA today approved Boehringer Ingelheim and Lilly's empagliflozin and linagliptin (Glyxambi) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.